JP2008503489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503489A5 JP2008503489A5 JP2007516793A JP2007516793A JP2008503489A5 JP 2008503489 A5 JP2008503489 A5 JP 2008503489A5 JP 2007516793 A JP2007516793 A JP 2007516793A JP 2007516793 A JP2007516793 A JP 2007516793A JP 2008503489 A5 JP2008503489 A5 JP 2008503489A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- aryl
- compound
- alkyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 105
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 72
- 125000001072 heteroaryl group Chemical group 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 62
- 125000003545 alkoxy group Chemical group 0.000 claims description 53
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 37
- 125000003342 alkenyl group Chemical group 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 35
- 150000004820 halides Chemical class 0.000 claims description 32
- 125000004442 acylamino group Chemical group 0.000 claims description 31
- 125000006413 ring segment Chemical group 0.000 claims description 31
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 29
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 150000002825 nitriles Chemical class 0.000 claims description 26
- 125000004423 acyloxy group Chemical group 0.000 claims description 25
- 125000005035 acylthio group Chemical group 0.000 claims description 25
- 125000003282 alkyl amino group Chemical group 0.000 claims description 25
- 125000004104 aryloxy group Chemical group 0.000 claims description 25
- 125000002950 monocyclic group Chemical group 0.000 claims description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 150000003857 carboxamides Chemical class 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000001769 aryl amino group Chemical group 0.000 claims description 16
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 13
- -1 bond to R 7 Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 10
- 125000004001 thioalkyl group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 9
- 125000003367 polycyclic group Chemical group 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000034951 Genetic Translocation Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001925 cycloalkenes Chemical class 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004560 pineal gland Anatomy 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000018964 sebaceous gland cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000008759 sweat gland cancer Diseases 0.000 claims 1
- 201000008753 synovium neoplasm Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 0 CCCCC[C@@](C#Cc1cccc(CN2O[C@@](CO)C([C@](C)O)[C@@]2C(*CCC(C)C)=O)c1)O Chemical compound CCCCC[C@@](C#Cc1cccc(CN2O[C@@](CO)C([C@](C)O)[C@@]2C(*CCC(C)C)=O)c1)O 0.000 description 12
- 125000003396 thiol group Chemical class [H]S* 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FTYAMAFJPVEFHV-UHFFFAOYSA-N CC(C)(C)CCN(CCN(C)C)Cc1cc(CN2OCCC2)ccc1 Chemical compound CC(C)(C)CCN(CCN(C)C)Cc1cc(CN2OCCC2)ccc1 FTYAMAFJPVEFHV-UHFFFAOYSA-N 0.000 description 1
- BLLWARIFNLSXIJ-UHFFFAOYSA-N CC(C)CC1(CN(C)C)CC1 Chemical compound CC(C)CC1(CN(C)C)CC1 BLLWARIFNLSXIJ-UHFFFAOYSA-N 0.000 description 1
- NQULBISGTHBUGM-UHFFFAOYSA-N CC(C)CCCN(C)C Chemical compound CC(C)CCCN(C)C NQULBISGTHBUGM-UHFFFAOYSA-N 0.000 description 1
- KOOQJINBDNZUTB-UHFFFAOYSA-N CC(C)CCN(C)C Chemical compound CC(C)CCN(C)C KOOQJINBDNZUTB-UHFFFAOYSA-N 0.000 description 1
- GDJHWTSEYBNSLE-VDQRMXPVSA-N CC(C)C[C@@H](CN(C)C)N(Cc1cc(CN2OC[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1Oc1ccccc1 Chemical compound CC(C)C[C@@H](CN(C)C)N(Cc1cc(CN2OC[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1Oc1ccccc1 GDJHWTSEYBNSLE-VDQRMXPVSA-N 0.000 description 1
- BCVGGABQFQPYCM-HRNNMHKYSA-N CC(C)C[C@@H](CN(C)C)N(Cc1cccc(CN(C2)OC[C@H]2[C@H](C)O)c1)Cc(c(F)ccc1)c1OC Chemical compound CC(C)C[C@@H](CN(C)C)N(Cc1cccc(CN(C2)OC[C@H]2[C@H](C)O)c1)Cc(c(F)ccc1)c1OC BCVGGABQFQPYCM-HRNNMHKYSA-N 0.000 description 1
- NUGYCJOASVLQJZ-IWPKVVQASA-N CC(C)C[C@@H](CN(C)C)NC(c1cc(-c(cccc2CN3OC[C@@H]([C@H](C)O)[C@H]3C(N[C@@H]3[C@@H](C)[C@H](C4)C(C)(C)[C@H]4C3)=O)c2OC)ccc1)=O Chemical compound CC(C)C[C@@H](CN(C)C)NC(c1cc(-c(cccc2CN3OC[C@@H]([C@H](C)O)[C@H]3C(N[C@@H]3[C@@H](C)[C@H](C4)C(C)(C)[C@H]4C3)=O)c2OC)ccc1)=O NUGYCJOASVLQJZ-IWPKVVQASA-N 0.000 description 1
- LNWXZJDCBFDBGN-RMTCHYSPSA-N CC(C)C[C@H](CN(C)C)N(Cc1cccc(CN2OC[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)c1)Cc(cccc1)c1N1CCOCC1 Chemical compound CC(C)C[C@H](CN(C)C)N(Cc1cccc(CN2OC[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)c1)Cc(cccc1)c1N1CCOCC1 LNWXZJDCBFDBGN-RMTCHYSPSA-N 0.000 description 1
- BAULSHLTGVOYKM-UHFFFAOYSA-N CCCCNC(c1ccccc1)=O Chemical compound CCCCNC(c1ccccc1)=O BAULSHLTGVOYKM-UHFFFAOYSA-N 0.000 description 1
- SPOUHGFMEBSMET-LJQANCHMSA-N CC[C@H]1CON(Cc2c[n](C)(C)cc(C#CCNC(C3=CCC=CC3)=O)c2)C1 Chemical compound CC[C@H]1CON(Cc2c[n](C)(C)cc(C#CCNC(C3=CCC=CC3)=O)c2)C1 SPOUHGFMEBSMET-LJQANCHMSA-N 0.000 description 1
- GKFLPKWYRCLXKZ-UHFFFAOYSA-N CN(Cc1ccccc1)CS Chemical compound CN(Cc1ccccc1)CS GKFLPKWYRCLXKZ-UHFFFAOYSA-N 0.000 description 1
- JSGDEZVECUMWQZ-UHFFFAOYSA-N CNCCCN(C)c1ccccc1 Chemical compound CNCCCN(C)c1ccccc1 JSGDEZVECUMWQZ-UHFFFAOYSA-N 0.000 description 1
- KUNCCMAQTBTWDW-WPXGONGXSA-N C[C@@H](C(C1)C(C)(C)[C@H]1C1)[C@H]1NC Chemical compound C[C@@H](C(C1)C(C)(C)[C@H]1C1)[C@H]1NC KUNCCMAQTBTWDW-WPXGONGXSA-N 0.000 description 1
- ULKQWFXEBMQTJW-HVMFKHOCSA-N C[C@@H]([C@H](CO)[C@@H](C(N[C@@H]1[C@@H](C)[C@H](C2)C(C)(C)[C@H]2C1)=O)NCc1cc(-c2cc(C(N[C@@H](CC(C)(C)C)CN(C)C)=O)ccc2)ccc1)O Chemical compound C[C@@H]([C@H](CO)[C@@H](C(N[C@@H]1[C@@H](C)[C@H](C2)C(C)(C)[C@H]2C1)=O)NCc1cc(-c2cc(C(N[C@@H](CC(C)(C)C)CN(C)C)=O)ccc2)ccc1)O ULKQWFXEBMQTJW-HVMFKHOCSA-N 0.000 description 1
- XUJVAIVDHYBQEC-QZHYPTKKSA-N C[C@@H]([C@H]1[C@@H](C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cc(C(C)(c3ccccc3)O)ccc2)O[C@H]1CO)O Chemical compound C[C@@H]([C@H]1[C@@H](C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cc(C(C)(c3ccccc3)O)ccc2)O[C@H]1CO)O XUJVAIVDHYBQEC-QZHYPTKKSA-N 0.000 description 1
- SAUXCLNBQWCYOR-VGEOPPHBSA-N C[C@@H]([C@H]1[C@@H](C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(-c3cccc(C(N[C@@H](Cc4ccccc4)CN(C)C)=O)c3)c2OC)OC1)O Chemical compound C[C@@H]([C@H]1[C@@H](C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(-c3cccc(C(N[C@@H](Cc4ccccc4)CN(C)C)=O)c3)c2OC)OC1)O SAUXCLNBQWCYOR-VGEOPPHBSA-N 0.000 description 1
- DBLMODCCBUXHLQ-GIOZQRIQSA-N C[C@@H]([C@H]1[C@@H](C=O)N(CC2CC(C#CCNC)=CCC2)O[C@H]1CO)O Chemical compound C[C@@H]([C@H]1[C@@H](C=O)N(CC2CC(C#CCNC)=CCC2)O[C@H]1CO)O DBLMODCCBUXHLQ-GIOZQRIQSA-N 0.000 description 1
- DTTABWBUOXQWNG-IEAZIUSSSA-N C[C@@H]([C@H]1[C@@H](C=O)N(Cc2cccc(C#CCN)c2)O[C@H]1CO)O Chemical compound C[C@@H]([C@H]1[C@@H](C=O)N(Cc2cccc(C#CCN)c2)O[C@H]1CO)O DTTABWBUOXQWNG-IEAZIUSSSA-N 0.000 description 1
- QWXJXVDEKZMGOT-ATJZJYQQSA-N C[C@H]([C@@H]1[C@H](C(NC/C=C(\C)/CCC=C(C)C)=O)N(Cc2cccc(C#CC(C)(c3ccccc3)O)c2)O[C@@H]1CO)O Chemical compound C[C@H]([C@@H]1[C@H](C(NC/C=C(\C)/CCC=C(C)C)=O)N(Cc2cccc(C#CC(C)(c3ccccc3)O)c2)O[C@@H]1CO)O QWXJXVDEKZMGOT-ATJZJYQQSA-N 0.000 description 1
- INPZKWUZSZBJSU-YEHREXKJSA-N C[C@H]([C@@H]1[C@H](C(NCC2CCCCC2)=O)N(Cc2cccc(C#CC3(CCCC3)O)c2)O[C@@H]1CO)O Chemical compound C[C@H]([C@@H]1[C@H](C(NCC2CCCCC2)=O)N(Cc2cccc(C#CC3(CCCC3)O)c2)O[C@@H]1CO)O INPZKWUZSZBJSU-YEHREXKJSA-N 0.000 description 1
- XCFVMVKTKRILNX-UHFFFAOYSA-N NC1(CCCCC1)S Chemical compound NC1(CCCCC1)S XCFVMVKTKRILNX-UHFFFAOYSA-N 0.000 description 1
- VEOFZVYGXYNXQN-UHFFFAOYSA-N O=C(c1ccccc1)NC=S Chemical compound O=C(c1ccccc1)NC=S VEOFZVYGXYNXQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58061604P | 2004-06-17 | 2004-06-17 | |
| US60/580,616 | 2004-06-17 | ||
| US65930105P | 2005-03-07 | 2005-03-07 | |
| US60/659,301 | 2005-03-07 | ||
| PCT/US2005/021524 WO2006009869A1 (en) | 2004-06-17 | 2005-06-17 | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008503489A JP2008503489A (ja) | 2008-02-07 |
| JP2008503489A5 true JP2008503489A5 (enExample) | 2012-07-26 |
| JP5064213B2 JP5064213B2 (ja) | 2012-10-31 |
Family
ID=35335774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516793A Expired - Fee Related JP5064213B2 (ja) | 2004-06-17 | 2005-06-17 | Ｂｃｌタンパク質と結合パートナーとの相互作用を阻害する化合物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7851637B2 (enExample) |
| EP (1) | EP1768966B1 (enExample) |
| JP (1) | JP5064213B2 (enExample) |
| KR (1) | KR101195351B1 (enExample) |
| CN (1) | CN101006065B (enExample) |
| AT (1) | ATE548359T1 (enExample) |
| AU (1) | AU2005265131B2 (enExample) |
| BR (1) | BRPI0511070A (enExample) |
| CA (1) | CA2570780C (enExample) |
| EC (1) | ECSP067099A (enExample) |
| ES (1) | ES2382383T3 (enExample) |
| IL (1) | IL179904A (enExample) |
| MA (1) | MA28702B1 (enExample) |
| MX (1) | MXPA06014754A (enExample) |
| NO (1) | NO20070324L (enExample) |
| NZ (1) | NZ552183A (enExample) |
| PL (1) | PL1768966T3 (enExample) |
| PT (1) | PT1768966E (enExample) |
| RU (1) | RU2416606C2 (enExample) |
| WO (1) | WO2006009869A1 (enExample) |
| ZA (1) | ZA200610405B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| US7851637B2 (en) | 2004-06-17 | 2010-12-14 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| EP1897956A1 (en) * | 2006-09-06 | 2008-03-12 | Lonza AG | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase |
| WO2009099677A2 (en) * | 2008-02-08 | 2009-08-13 | Aileron Therapeutics, Inc. | Therapeutic peptidomimetic macrocycles |
| AU2009263037B2 (en) * | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| NZ591025A (en) * | 2008-08-21 | 2013-01-25 | Alvine Pharmaceuticals Inc | Formulation for oral administration of proteins |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| RU2497822C2 (ru) * | 2008-12-05 | 2013-11-10 | Эббви Инк. | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UY32668A (es) * | 2009-05-26 | 2010-12-31 | Abbott Lab | Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US10709692B2 (en) * | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
| WO2017172826A1 (en) | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) * | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3829594A1 (de) * | 1988-09-01 | 1990-03-15 | Bayer Ag | Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
| DE3926822A1 (de) * | 1989-08-14 | 1991-02-21 | Hoechst Ag | Peptide mit bradykinin-antagonistischer wirkung |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| HU222234B1 (hu) | 1990-05-18 | 2003-05-28 | Aventis Pharma Deutschland Gmbh. | Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására |
| US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| DE69426604T2 (de) | 1993-11-24 | 2001-05-10 | Dupont Pharmaceuticals Co., Wilmington | Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| US5686434A (en) * | 1993-11-26 | 1997-11-11 | Pfizer Inc. | 3-aryl-2-isoxazolines as antiinflammatory agents |
| EP0749428B1 (en) | 1994-03-09 | 1998-07-29 | Pfizer Inc. | Isoxazoline compounds as inhibitors of tnf release |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| IT1283836B1 (it) | 1996-08-28 | 1998-04-30 | Viv Int Spa | Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| WO1998050031A1 (en) * | 1997-05-07 | 1998-11-12 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU7105800A (en) | 1999-09-01 | 2001-03-26 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| KR20040108528A (ko) | 2001-05-30 | 2004-12-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｂｃｌ2 군 단백질의 소분자 길항제 |
| US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| US7851637B2 (en) | 2004-06-17 | 2010-12-14 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
-
2005
- 2005-06-17 US US11/156,364 patent/US7851637B2/en not_active Expired - Fee Related
- 2005-06-17 AU AU2005265131A patent/AU2005265131B2/en not_active Ceased
- 2005-06-17 RU RU2007101276/04A patent/RU2416606C2/ru not_active IP Right Cessation
- 2005-06-17 PT PT05762701T patent/PT1768966E/pt unknown
- 2005-06-17 EP EP05762701A patent/EP1768966B1/en not_active Expired - Lifetime
- 2005-06-17 BR BRPI0511070-0A patent/BRPI0511070A/pt active Search and Examination
- 2005-06-17 CA CA2570780A patent/CA2570780C/en not_active Expired - Fee Related
- 2005-06-17 KR KR1020077001087A patent/KR101195351B1/ko not_active Expired - Fee Related
- 2005-06-17 AT AT05762701T patent/ATE548359T1/de active
- 2005-06-17 MX MXPA06014754A patent/MXPA06014754A/es active IP Right Grant
- 2005-06-17 NZ NZ552183A patent/NZ552183A/en not_active IP Right Cessation
- 2005-06-17 PL PL05762701T patent/PL1768966T3/pl unknown
- 2005-06-17 ES ES05762701T patent/ES2382383T3/es not_active Expired - Lifetime
- 2005-06-17 CN CN2005800281288A patent/CN101006065B/zh not_active Expired - Fee Related
- 2005-06-17 JP JP2007516793A patent/JP5064213B2/ja not_active Expired - Fee Related
- 2005-06-17 WO PCT/US2005/021524 patent/WO2006009869A1/en not_active Ceased
-
2006
- 2006-12-07 IL IL179904A patent/IL179904A/en not_active IP Right Cessation
- 2006-12-12 ZA ZA200610405A patent/ZA200610405B/en unknown
- 2006-12-20 EC EC2006007099A patent/ECSP067099A/es unknown
- 2006-12-29 MA MA29588A patent/MA28702B1/fr unknown
-
2007
- 2007-01-17 NO NO20070324A patent/NO20070324L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503489A5 (enExample) | ||
| RU2007101276A (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ДЛЯ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ Bcl БЕЛКОВ С КОМПОНЕНТАМИ ПО СВЯЗЫВАНИЮ | |
| RU2468016C2 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ | |
| JP2010510214A5 (enExample) | ||
| US8900562B2 (en) | Semi-fluorinated block copolymers for delivery of therapeutic agents | |
| JP2014533699A5 (enExample) | ||
| RU2009121808A (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ | |
| JP5008258B2 (ja) | 含硫黄ホスホリピド誘導体 | |
| CY1122761T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
| JP2008515985A5 (enExample) | ||
| EP1772142A3 (en) | Organic compounds | |
| JP2014503574A5 (enExample) | ||
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| CY1112499T1 (el) | Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων | |
| EA201001127A1 (ru) | Производные пиридина | |
| EP1818325A3 (en) | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | |
| JP2011510068A5 (enExample) | ||
| CU23967B1 (es) | Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial | |
| JP2012509349A5 (enExample) | ||
| TW200509926A (en) | Fused compounds that inhibit vanilloid receptor subtype 1 VR1) receptor | |
| JP2018109017A5 (enExample) | ||
| EP2620145A3 (en) | 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ | |
| JP2015522551A5 (enExample) | ||
| WO2017151425A1 (en) | Hsp90 inhibitor drug conjugates | |
| WO2024141128A3 (zh) | Sting抑制剂前药及其医药用途 |